← Human Trials & Peer-Reviewed Studies
Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
Plain-language guide to PMID 27734257 (2017): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 124 patients.
Key Facts
- PMID
- 27734257
- Journal
- Endocrine
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Clarke BL et al. (6 authors)
- DOI
- 10.1007/s12020-016-1141-0
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
The objective of this study was to determine the effect of recombinant human parathyroid hormone, rhPTH(1-84), on phosphate and vitamin D metabolite levels in patients with hypoparathyroidism.
Why It Was Studied
In hypoparathyroidism, inappropriately low levels of parathyroid hormone lead to unbalanced mineral homeostasis.
Predefined endpoints related to phosphate homeostasis and vitamin D metabolism were analyzed.
Who Took Part
The study group was 124 patients.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
Neither the patients nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.
A time span of 24 weeks appears in the methods.
What Was Measured
In hypoparathyroidism, inappropriately low levels of parathyroid hormone lead to unbalanced mineral homeostasis.
Predefined endpoints related to phosphate homeostasis and vitamin D metabolism were analyzed.
Topics PubMed links to this paper include Calcium, Homeostasis, Hormone Replacement Therapy, Hypoparathyroidism, Parathyroid Hormone, Phosphates and Recombinant Proteins.
The authors tagged it with the keywords Vitamin D and rhPTH(1–84).
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 124 patients over 24 weeks.
The publication is from 2017 (Endocrine), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.